Skip to main content
Clinical Trials/NCT02579304
NCT02579304
Unknown
Not Applicable

Feasibility, Safety and Diagnostic Value of Transbronchial Lung Cryobiopsy in the Work-up of Diffuse Interstitial Lung Diseases.

KU Leuven1 site in 1 country20 target enrollmentJanuary 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Interstitial Lung Disease
Sponsor
KU Leuven
Enrollment
20
Locations
1
Primary Endpoint
histopathological agreement
Last Updated
7 years ago

Overview

Brief Summary

Evaluating the diagnostic value of transbronchial lung cryobiopsy (TBLC) as well as its procedural feasibility and safety in a prospective series of 20 patients with diffuse interstitial lung diseases (DILD) who are referred for invasive histopathological diagnostics

Detailed Description

Before one is able to state that TBLC is a technique that is an alternative for VATS biopsy, the diagnostic value of TBLC should be assessed and the value of the histopathological sampling should be compared with what is achieved by surgical lung biopsy. For this purpose direct comparison between VATS biopsy and TBLC is unavoidable. By including TBLC in the work-up of patients with DILD in which histopathological assessment is indicated (as proposed by MDD), we want to assess 3 major points of concern. Agreement for the histopathological diagnosis between VATS biopsy and TBLC. Value of TBLC in the specific diagnosis in ILD.

Registry
clinicaltrials.gov
Start Date
January 2019
End Date
June 2023
Last Updated
7 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
KU Leuven
Responsible Party
Principal Investigator
Principal Investigator

Yserbyt Jonas

MD

KU Leuven

Eligibility Criteria

Inclusion Criteria

  • - Case of DILD presented at the MDD
  • Referral for VATS biopsy as advised by MDD.
  • Informed consent available
  • Age \> 18
  • FVC \> 50%pred
  • DLCO \> 40%pred
  • PaO2 \> 65 mmHg, pCO2 \< 45 mmHg
  • No exclusion criteria

Exclusion Criteria

  • - Age \> 75
  • PAPS \>40mmHg as measured on transthoracic cardiac ultrasound
  • Platelet count \<100000/µl
  • INR \> 1.4
  • Diffuse bullous lung disease
  • Active anti-platelet or anticoagulant treatment
  • Active heart failure or unstable coronary heart disease
  • Patients unfit for VATS under general anaesthesia as assessed by the surgeon and/or anesthesiologist

Outcomes

Primary Outcomes

histopathological agreement

Time Frame: 2 years

Histopathological diagnostic intra-observer agreement between Video-assisted thoracosopic surgery biopsy and TBLC (kappa value)

Secondary Outcomes

  • procedural safety : bleeding(periprocedural 1 hour)
  • procedural safety : bleeding (2)(periprocedural 1 hour)
  • procedural safety : bleeding (3)(periprocedural 1 hour)
  • procedural safety : penumothorax(periprocedural 1 hour)

Study Sites (1)

Loading locations...

Similar Trials